



PROFICIENCY TESTING SERVICE
AMERICAN ASSOCIATION OF BIOANALYSTS
 205 West Levee St. ♦ Brownsville, TX 78520-5596
 800-234-5315 ♦ 281-436-5357 ♦ Fax 713-781-5008

PARTICIPANT STATISTICS

FIRST QUADRIMESTER 2019

HEPATITIS MARKERS

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Abbott Architect		3		3				3			3			3	
Siemens Advia		3		3				3			3			3	
Total Population	1	12	0	13	0	0	1	12	0	0	13	0	4	9	0
Flagging	***			***			***			***			***		

*Due to a lack of participant consensus, Specimen 5 was not evaluated. The intended result was Positive.

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Abbott Architect	5			5			5			5			5		
Bio-Rad MONOLISA EIA	5			5			5			5			5		
Roche Elecsys	4			4			4			4			4		
Siemens Advia	6			6			6			6			6		
Total Population	24	0	0	24	0	0	24	0	0	24	0	0	24	0	0
Flagging	***			***			***			***			***		

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Would refer	Neg	Pos	Would refer	Neg	Pos	Would refer	Neg	Pos	Would refer	Neg	Pos	Would refer
Abbott Architect		13		13				12	1	13				12	
OraSure OraQuick Rapid		14		13	1			14		14				14	
Ortho ELISA		5		5				5		5				5	
Roche Elecsys		5	3	8				5	3	8				8	
Siemens Advia		8		8				8		8				8	
Total Population	0	54	3	56	1	0	0	53	4	57	0	0	56	0	0
Flagging	***			***	***		***			***	***		***		***

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Bio-Rad MONOLISA EIA	1	2			3			3			3			3	
Roche Elecsys		3			3			3			3			3	
Siemens Advia	2	1			3			3			3			3	
Total Population	6	8	2	0	16	0	0	16	0	16	0	0	0	16	0
Flagging				***			***			***			***		

*Due to a lack of participant consensus, Specimen 1 was not evaluated. The intended result was Positive.

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Abbott Core-M	5			5			5			5			5		
Bio-Rad MONOLISA EIA	5			5			5			5			5		
Roche Elecsys	4			4			4			4			4		
Siemens Advia	5			5			5			5			5		
Total Population	23	0	0	22	1	0	23	0	0	23	0	0	23	0	0
Flagging	***			***	***		***			***			***		

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Abbott Architect	5			5			5			5			5		
Bio-Rad MONOLISA EIA	4			3		1	4			4			4		
DiaSorin ETI-AB-AUK Plus	3			3			3			3			3		
Roche Elecsys	4	1		5			5			5			5		
Siemens Advia	3			3			3			3			3		
Total Population	23	1	0	23	0	1	24	0	0	0	24	0	1	23	0
Flagging	***			***			***			***			***		

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Total Population	2	0	0	0	2	0	2	0	0	2	0	0	2	0	0
Flagging	***			***			***			***			***		

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Reac, conf	Neg	Pos	Reac, conf	Neg	Pos	Reac, conf	Neg	Pos	Reac, conf	Neg	Pos	Reac, conf
Abbott Architect	9			6		3		6		3		9			9
Bio-Rad EIA-Proc A	5			5				5			5			5	
Bio-Rad MONOLISA Ultra	3			3				3			3			3	
DiaSorin ETI-MAK-2 Plus	2	1		3				3		2	1		3		
Roche Elecsys	9			5		4		5		4		9			9
Siemens Advia	10			10				10			9	1		10	
Siemens Immulite	1	2		3				3			3			3	
Total Population	47	3	0	0	43	7	0	43	7	48	2	0	49	1	0
Flagging	***			***			***			***			***		

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.